Ductal Carcinoma in Situ

Definition

• DCIS is a non-invasive breast cancer where malignant epithelial cells proliferate within the mammary ducts but do not invade the basement membrane.
• Considered Stage 0 breast cancer in the AJCC staging system.

Pathophysiology

• Originates in the terminal duct–lobular unit.
• Neoplastic cells are confined by the basement membrane and surrounded by intact myoepithelial cells.
• No vascular or stromal invasion → no metastatic potential at this stage.
• However, untreated DCIS can progress to invasive ductal carcinoma (IDC) in ~20–30% of cases.

Risk Factors

• Similar to invasive breast cancer:
  • Age (50–60 years most common)
  • Family history, BRCA mutations
  • Estrogen exposure (early menarche, late menopause, HRT)
  • Prior chest irradiation

Diagnosis

• Often asymptomatic; detected via screening mammography.
• Mammographic finding: microcalcifications in a clustered or linear distribution.
• Confirmed by core needle biopsy.
• Histological grading: low, intermediate, or high-grade DCIS.

Clinical Significance

• Not life-threatening if treated, but carries a risk of local recurrence and progression to invasive cancer.
• Recurrence risk depends on:
  • Size and grade of lesion
  • Margins after surgery
  • Patient age
  • Hormone receptor (ER/PR) status

Treatment Approaches

1. Surgery

• Breast-conserving surgery (lumpectomy) ± radiation
• Mastectomy for extensive/multifocal DCIS or contraindication to radiation

2. Radiation Therapy

• Post-lumpectomy, reduces local recurrence risk by ~50%.

3. Endocrine Therapy

• For ER+ DCIS after surgery (with or without radiation):
  • Tamoxifen (premenopausal and postmenopausal women)
  • Aromatase inhibitors (e.g., anastrozole) (postmenopausal women)
  • Reduces ipsilateral recurrence and contralateral breast cancer risk.

4. Chemotherapy

• Not indicated (no systemic invasion, no metastasis).

Role for the Oncology Pharmacist

• Medication management: Counsel on tamoxifen vs. AI therapy: duration (typically 5 years), side effects (VTE risk, endometrial cancer for tamoxifen; osteoporosis, arthralgia for AIs).
• Supportive care:
  • Advise on bone health monitoring if AIs are used.
  • Drug interaction checks (e.g., CYP2D6 inhibitors reducing tamoxifen activation).
• Patient education:
  • Emphasize adherence to endocrine therapy.
  • Clarify that DCIS itself is not life-threatening but requires treatment to prevent invasive recurrence.
• Multidisciplinary input: Collaborate on treatment plans with oncologists, surgeons, radiation oncologists.

Summary

DCIS is a precancerous, stage 0 breast lesion confined to ducts. Mainstay of treatment is surgery ± radiation, with endocrine therapy for ER+ cases. No role for chemotherapy. Pharmacists are crucial in managing endocrine therapy, monitoring toxicities, preventing interactions, and improving adherence.